Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Biomarker for psychiatric and neurological disorders

a psychiatric and neurological disorder and biomarker technology, applied in the field of biomarkers for psychiatric/neurological disorders, can solve the problems of variability, inability to put markers to practical use in view of accuracy, cost, etc., and achieve the effect of rapid and simple diagnosis, easy collection and quantification

Inactive Publication Date: 2018-05-03
RESVO INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a biomarker for diagnosis and treatment of psychiatric and neurological disorders. The biomarker can be easily collected and measured from a blood sample, making the diagnosis process faster and simpler.

Problems solved by technology

However, diagnoses using these criteria are performed by, for example, a medical examination by interview with patients and thus have had the problem of producing variations depending on the evaluator.
However, these markers are not put to practical use in view of accuracy, easiness to practice, cost, and the like.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarker for psychiatric and neurological disorders
  • Biomarker for psychiatric and neurological disorders
  • Biomarker for psychiatric and neurological disorders

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0083]Poly IC (polyriboinosinic-polyribocytidilic acid) (Sigma Co., Ltd.) dissolved in saline was intraperitoneally administered in an amount of 4 mg / kg to a Wistar rat at day 15 of gestation before normal delivery to prepare maternal immune activation model rats (MIA rats) which were schizophrenic and autistic model animals. The MIA rat is one of psychiatric / neurological disorder model animals (see Limin Shi et al, J. Neurosci. 2003 Jan. 1; 23(1): 297-302 and Arata Oh-Nishi et al, Brain Research, Volume 1363, 6 Dec. 2010, Pages 170-179). Only an equal volume of saline was intraperitoneally administered to another Wistar rat at day 15 of gestation before normal delivery to prepare control rats (hereinafter, referred to as “control” rats) as a control group. The MIA rats had significantly attenuated PPI compared to the control rats and were confirmed to be capable of being used as psychiatric / neurological disorder model animals.

[0084]The sera of the MIA rats (12-week old) and the con...

example 2

[0086]A rat-derived κ immunoglobulin chain C region (SEQ ID NO: 4) was used as an antigen and administered to a rabbit for immunization to prepare an antibody (anti-Ig κ-C antibody). Using the same method as that in Example 1, MIA rats and control rats were prepared. The sera of the MIA rats (12-week old, N=7) and the control rats (12-week old, N=7) were denatured only with SDS (100° C., 5 minutes) and subjected to electrophoresis with SDS-polyacrylamide gel to separate protein. Thereafter, Western blotting was carried out (gel: 10 to 20%, primary antibody (1:1,000), secondary antibody (1:5,000)) (FIG. 4). The anti-Ig κ-C antibody was used as a primary antibody, and an anti-rabbit IgG-HRP (from Chemi-Con Co., Ltd.) was used as a secondary antibody.

[0087]The intensity of a band of about 25 kDa significantly increased in the MIA rats (“Poly IC” in FIG. 4) compared to that in the control rats (“Saline” in FIG. 4) (FIG. 4(2)). The band of about 25 kDa is the free κ immunoglobulin chain ...

example 3

[0088]The amounts of inflammatory cytokines in the serum were measured in the MIA rats (“Poly IC” in the table, 12-week old, N=7) and the control rats (“Saline” in the table, 12-week old, N=7) of Example 2. The measurement of the amount of inflammatory cytokines used Quantikine ELASA Rat IL-1β, IL-6, and TNF-α (from R&D Co., Ltd.).

TABLE 1Concentration of Inflammatory Cytokine in SerumIL-6 (pg / ml)IL-1 beta (pg / ml)TNF-alpha (pg / ml)SalineN.DN.DN.DPoly ICN.DN.DN.D(N.D (N.D (N.D

[0089]No increase of the inflammatory cytokines in sera was observed in the MIA rats (“Poly IC” in the table) and the control rats (“Saline” in the table).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free κ immunoglobulin chains and free λ immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free κ immunoglobulin chains, free λ immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects. The biomarker enables more effective tests and diagnoses to be conducted combining inflammatory cytokines in the blood of patients with psychiatric and neurological disorders.

Description

TECHNICAL FIELD[0001]The present invention relates to a biomarker for a psychiatric / neurological disorder, particularly a biomarker for diagnosing a psychiatric / neurological disorder. The present invention also relates to a test kit for a psychiatric / neurological disorder for detecting the biomarker, and a test method for a psychiatric / neurological disorder using the biomarker.BACKGROUND ART[0002]Diagnosis criteria, such as DMSIV-TR, ICD-10, and PANSS, are currently used as indications in diagnosing psychiatric / neurological disorders, such as schizophrenia, autism, and Alzheimer's disease. However, diagnoses using these criteria are performed by, for example, a medical examination by interview with patients and thus have had the problem of producing variations depending on the evaluator. Thus, there has been a need for a biomarker as an objective biological indication.[0003]Attempts have also been previously made to search for biomarkers for diagnosing psychiatric / neurological disor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68C07K16/42
CPCC07K16/42G01N2333/545G01N33/6857G01N33/6863G01N33/6869G01N33/6893G01N33/6896G01N2333/5412G01N2800/304G01N2800/302G01N2800/301G01N2800/2821G01N2333/525
Inventor OHNISHI, ARATAMINAMIMOTO, TAKAFUMISUHARA, TETSUYA
Owner RESVO INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com